ମଳାଶୟ କର୍କଟ
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer
କେଉଁଠିକୁ ଯିବେ
ଏହି ଟ୍ରାଏଲ୍ ପାଇଁ ଭାରତରେ 5 ଟି ହସ୍ପିଟାଲ୍ ରୋଗୀ ନେଉଛନ୍ତି।
ରେଜିଷ୍ଟ୍ରି ସାରାଂଶ (ଟେକ୍ନିକାଲ୍)
The purpose of this study is to compare how long the participants are disease-free (progression-free survival) when treated with amivantamab and chemotherapy with 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, oxaliplatin (mFOLFOX6) or 5-fluorouracil, leucovorin calcium (folinic acid) or levoleucovorin, and irinotecan hydrochloride (FOLFIRI) versus cetuximab and mFOLFOX6 or FOLFIRI in adult participants with Kirsten rat sarcoma viral oncogene homolog (KRAS)/ Neuroblastoma RAS viral oncogene homolog (NRAS) and v-Raf murine sarcoma viral oncogene homolog B1 (BRAF) wild type…
ସ୍ପୋନ୍ସର: Janssen Research & Development, LLC
NCT06662786 on ClinicalTrials.gov
ରେଜିଷ୍ଟ୍ରିରେ ଶେଷ ଅପଡେଟ୍ 25 Sep 2026 · ଆମେ 20 Oct 2026 ରେ ପଢିଲୁ